Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVDL Avadel Pharmaceuticals	$14.81 -2.8%	$10.89	$6.38 ▼ $16.66	$1.44B	1.47	1.34 million shs	1.37 million shs
CADL Candel Therapeutics	$5.71 -4.0%	$5.85	$3.79 ▼ $14.60	$313.48M	-0.88	1.04 million shs	396,463 shs
EVO Evotec	$3.57 -1.9%	$4.00	$2.84 ▼ $5.64	$1.27B	1.67	95,823 shs	33,199 shs
PAHC Phibro Animal Health	$31.94 -1.6%	$28.31	$16.16 ▼ $32.95	$1.29B	0.8	259,379 shs	205,444 shs

7 Stocks to Ride The A.I. Megaboom

We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVDL Avadel Pharmaceuticals	0.00%	+11.32%	+38.17%	+66.92%	-7.64%
CADL Candel Therapeutics	0.00%	-2.30%	-15.24%	+9.58%	+4.75%
EVO Evotec	0.00%	-3.19%	-14.55%	-23.04%	+8.66%
PAHC Phibro Animal Health	0.00%	+5.84%	+11.24%	+39.67%	+55.01%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AVDL Avadel Pharmaceuticals	2.6708 of 5 stars	3.6	3.0	0.0	0.0	2.0	1.7	0.6
CADL Candel Therapeutics	2.3312 of 5 stars	3.6	2.0	0.0	0.0	1.7	1.7	0.6
EVO Evotec	1.5247 of 5 stars	3.3	2.0	0.0	0.0	1.6	0.0	0.6
PAHC Phibro Animal Health	3.4317 of 5 stars	0.9	2.0	2.5	1.1	2.0	3.3	2.5

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVDL Avadel Pharmaceuticals	3.14	Buy	$19.67	32.79% Upside
CADL Candel Therapeutics	3.20	Buy	$22.00	285.29% Upside
EVO Evotec	2.50	Moderate Buy	$5.40	51.26% Upside
PAHC Phibro Animal Health	1.83	Reduce	$24.40	-23.61% Downside

Current Analyst Ratings Breakdown

Latest CADL, EVO, AVDL, and PAHC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/21/2025	AVDL Avadel Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$13.00 ➝ $20.00
8/14/2025	EVO Evotec	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$8.00 ➝ $7.00
8/8/2025	AVDL Avadel Pharmaceuticals	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
8/8/2025	AVDL Avadel Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/8/2025	AVDL Avadel Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$22.00 ➝ $24.00
7/18/2025	AVDL Avadel Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy	$22.00
7/9/2025	CADL Candel Therapeutics	Brookline Capital Management Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/7/2025	PAHC Phibro Animal Health	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight	$25.00 ➝ $35.00
6/30/2025	CADL Candel Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$23.00
6/25/2025	PAHC Phibro Animal Health	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Equal Weight ➝ Equal Weight	$21.00 ➝ $26.00
6/16/2025	PAHC Phibro Animal Health	BNP Paribas Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold

(Data available from 8/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVDL Avadel Pharmaceuticals	$169.12M	8.50	N/A	N/A	$0.77 per share	19.23
CADL Candel Therapeutics	$120K	2,612.33	N/A	N/A	$1.41 per share	4.05
EVO Evotec	$862.40M	1.47	N/A	N/A	$2.91 per share	1.23
PAHC Phibro Animal Health	$1.19B	1.09	$2.08 per share	15.36	$6.34 per share	5.04

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVDL Avadel Pharmaceuticals	-$48.83M	-$0.03	N/A	246.83	N/A	-1.32%	-3.73%	-1.73%	11/11/2025 (Estimated)
CADL Candel Therapeutics	-$55.18M	-$0.69	N/A	N/A	N/A	N/A	-41.00%	-26.81%	11/13/2025 (Estimated)
EVO Evotec	-$212.18M	N/A	0.00	N/A	N/A	-20.14%	-16.94%	-8.14%	11/5/2025 (Estimated)
PAHC Phibro Animal Health	$2.42M	$0.78	40.95	15.21	0.54	2.68%	30.51%	6.89%	8/27/2025 (Estimated)

Latest CADL, EVO, AVDL, and PAHC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/27/2025	Q4 2025	PAHC Phibro Animal Health	$0.52	N/A	N/A	N/A	$362.24 million	N/A
8/14/2025	Q2 2025	CADL Candel Therapeutics	-$0.17	-$0.09	+$0.08	-$0.09	N/A	N/A
8/7/2025	Q2 2025	AVDL Avadel Pharmaceuticals	$0.02	$0.10	+$0.08	$0.10	$60.28 million	$68.13 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVDL Avadel Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CADL Candel Therapeutics	N/A	N/A	N/A	N/A	N/A
EVO Evotec	N/A	N/A	N/A	N/A	N/A
PAHC Phibro Animal Health	$0.48	1.50%	N/A	61.54%	N/A

Latest CADL, EVO, AVDL, and PAHC Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/29/2025	PAHC Phibro Animal Health	quarterly	$0.12	1.71%	9/3/2025	9/3/2025	9/24/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVDL Avadel Pharmaceuticals	N/A	2.79	2.38
CADL Candel Therapeutics	0.01	7.04	7.04
EVO Evotec	0.42	1.58	1.49
PAHC Phibro Animal Health	2.67	2.91	1.23

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVDL Avadel Pharmaceuticals	69.19%
CADL Candel Therapeutics	13.93%
EVO Evotec	5.81%
PAHC Phibro Animal Health	99.34%

Insider Ownership

Company	Insider Ownership
AVDL Avadel Pharmaceuticals	5.20%
CADL Candel Therapeutics	16.60%
EVO Evotec	N/A
PAHC Phibro Animal Health	50.07%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVDL Avadel Pharmaceuticals	70	97.10 million	92.05 million	Optionable
CADL Candel Therapeutics	60	54.90 million	45.78 million	Optionable
EVO Evotec	4,827	355.11 million	N/A	Not Optionable
PAHC Phibro Animal Health	1,940	40.53 million	20.24 million	Optionable

CADL, EVO, AVDL, and PAHC Headlines

Recent News About These Companies

Nuveen LLC Makes New Investment in Phibro Animal Health Corporation $PAHC

August 25 at 3:41 AM | marketbeat.com

Public Sector Pension Investment Board Has $1.70 Million Position in Phibro Animal Health Corporation $PAHC

August 23 at 4:25 AM | marketbeat.com

Q4 EPS Forecast for Phibro Animal Health Reduced by Analyst

August 23 at 3:59 AM | americanbankingnews.com

Insights Into Phibro (PAHC) Q4: Wall Street Projections for Key Metrics

August 22 at 12:36 PM | msn.com

Q1 EPS Forecast for Phibro Animal Health Raised by Analyst

August 22 at 7:56 AM | marketbeat.com

Phibro Animal Health (NASDAQ:PAHC) Hits New 12-Month High - Here's Why

August 21, 2025 | marketbeat.com

Phibro Animal Health (PAHC) Projected to Post Earnings on Wednesday

August 21, 2025 | marketbeat.com

Phibro Animal Health Corporation to Host Webcast and Conference Call on Fourth Quarter and Fiscal Year 2025 Results

August 20, 2025 | businesswire.com

PAHC vs. BSX: Which Stock Is the Better Value Option?

August 20, 2025 | zacks.com

Should Value Investors Buy Phibro Animal Health (PAHC) Stock?

August 20, 2025 | zacks.com

PAHC Stock Up 76.4% in a Year: What's Driving the Rally?

August 20, 2025 | zacks.com

Phibro Animal Health Corporation $PAHC Shares Purchased by LPL Financial LLC

August 19, 2025 | marketbeat.com

Independent Advisor Alliance Takes $577,000 Position in Phibro Animal Health Corporation (NASDAQ:PAHC)

August 16, 2025 | marketbeat.com

Phibro Animal Health Corporation (NASDAQ:PAHC) Shares Sold by Mackenzie Financial Corp

August 11, 2025 | marketbeat.com

Phibro Animal Health Corp. Financials | PAHC | Barron's

August 10, 2025 | barrons.com

Zacks Research Has Strong Forecast for PAHC FY2026 Earnings

August 9, 2025 | marketbeat.com

Phibro Animal Health Corporation (NASDAQ:PAHC) Given Consensus Rating of "Reduce" by Brokerages

August 5, 2025 | marketbeat.com

PAHC vs. LMAT: Which Stock Should Value Investors Buy Now?

August 4, 2025 | zacks.com

Empirical Financial Services LLC d.b.a. Empirical Wealth Management Makes New Investment in Phibro Animal Health Corporation (NASDAQ:PAHC)

August 4, 2025 | marketbeat.com

15,477 Shares in Phibro Animal Health Corporation (NASDAQ:PAHC) Acquired by Universal Beteiligungs und Servicegesellschaft mbH

August 4, 2025 | marketbeat.com

KLP Kapitalforvaltning AS Has $90,000 Stake in Phibro Animal Health Corporation (NASDAQ:PAHC)

August 1, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

CADL, EVO, AVDL, and PAHC Company Descriptions

Avadel Pharmaceuticals NASDAQ:AVDL

$14.81 -0.43 (-2.82%)

Closing price 04:00 PM Eastern

Extended Trading

$14.80 -0.01 (-0.03%)

As of 05:25 PM Eastern

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

Candel Therapeutics NASDAQ:CADL

$5.71 -0.24 (-4.03%)

Closing price 04:00 PM Eastern

Extended Trading

$5.85 +0.14 (+2.45%)

As of 05:36 PM Eastern

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.

Evotec NASDAQ:EVO

$3.57 -0.07 (-1.92%)

Closing price 04:00 PM Eastern

Extended Trading

$3.56 -0.01 (-0.28%)

As of 05:25 PM Eastern

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health. It has collaboration agreements with SK bioscience, JingXin, Carrick Therapeutics, Sernova, Topas Therapeutics, Exscientia, CONBA Group, Centrexion, Sanofi/NIH, Kazia Therapeutics, Bristol Myers Squibb, Topas Therapeutics, Immunitas, Exscientia, and Bayer; and Inserm, the French National Institute of Health and Medical Research, Lille University Hospital, and Inserm Transfert to identify novel therapeutic targets and diagnostic and prognostic markers in obesity and metabolic diseases, as well as collaboration with CHDI Foundation, Inc.; and a strategic partnership with Dewpoint Therapeutics to advance its portfolio targeting biomolecular condensates as a novel domain for therapeutic intervention towards the clinic, as well as research collaboration with Pfizer for metabolic and infectious diseases. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.

Phibro Animal Health NASDAQ:PAHC

$31.94 -0.52 (-1.60%)

Closing price 04:00 PM Eastern

Extended Trading

$31.98 +0.04 (+0.11%)

As of 04:10 PM Eastern

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in development, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was founded in 1946 and is headquartered in Teaneck, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time